Sequencing antibody-drug conjugates adds complexity to recurrent endometrial cancer treatment

Therapy sequencing for recurrent endometrial cancer is becoming increasingly complex as immunotherapy moves earlier in the treatment pathway and antibody-drug conjugates (ADCs) gain traction.

Experts note that ADCs are attractive after progression on frontline regimens because they can deliver potent cytotoxic agents directly to tumor cells, addressing a setting with limited options.

However, no consensus algorithm exists for positioning ADCs relative to chemotherapy, anti-angiogenic agents, or other later-line therapies. Trastuzumab deruxtecan illustrates both promise and challenges, requiring careful counseling about nausea, cytopenias, fatigue, and potential pulmonary toxicity, along with close monitoring.